| Message: | CJC-1295 was developed for clinical trials in the year 2000. The drug was originally synthesized to remove visceral fat deposits in AIDS patients. CJC 1295 was ultimately successful on all research subjects, as increasing the level of growth hormone in the body proved to increase fat loss.
Various experiments have been conducted to test the effectiveness of CJC-1295 in vivo and the Journal of Clinical Endocrinology & Metabolism has reported dose-dependent increases in mean plasma GH concentrations by 2-10 fold for more than 6 days and increased IGF-1 concentrations 1.5-3 fold for 9-11 days after a single injection
.
Not only that but they proved the mean half life to be 5.8-8.1 days and after multiple doses showed mean IGF-1 levels remained above baseline for up to 28 days following! No serious adverse reactions were reported in any group.
Another very positive benefit of CJC-1295/CJC-1293 is its ability to promote slow wave sleep. Slow wave sleep is also known as deep sleep and is the portion of sleep responsible for the highest level of muscle growth and memory retention. SWS are decreased significantly in older adults and also with people who tend to exercise later in the evening.
This peptide has a benefit to side effect ratio that exceeds all others currently being legally sold and would make a great addition to ones training regimen or post cycle therapy. |
my account
